It is interesting to note the RESILIENCE trial using sorafenib with Capecitabine did not improve PFS and OS for patients with advanced HER2 negative breast cancer, in which ~69% of the patients were with HR positive breast cancer [34]. Here, ERBB2 is linked to breast cancer.